3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
2
Sarcoma
1
Gynecologic
1
Genitourinary
1
Dermatologic
1
Breast
1
Conditions
Sarcoma
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Melanoma
1
Kidney Neoplasms
1
Colorectal Neoplasms
1
Breast Neoplasms
1
Interventions
Nivolumab
24
pembrolizumab
21
Specimen Handling
17
Ipilimumab
16
Magnetic Resonance Spectroscopy
11
CTLA-4 Antigen
8
Opdualag
6
Cyclophosphamide
6
Biopsy
6
trametinib
5
relatlimab
5
binimetinib
5
fludarabine phosphate
4
fludarabine
4
dabrafenib
4
cemiplimab
4
atezolizumab
4
X-Rays
4
Paclitaxel
4
Immunoglobulin G
4
Disulfides
4
Temozolomide
3
Standard of Care
3
Introns
3
Interferon alpha-2
3
Gemcitabine
3
Carboplatin
3
Blood Specimen Collection
3
ulixertinib
2
sargramostim
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Genetic Counseling
×
Dermatologic
×
30 days
×
Clear all
NCT05225428
2026-05-22
VERDI
Dana-Farber Cancer Institute
Phase NA
Recruiting
1,020 enrolled